A PHASE I, MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED HIV-1 VACCINE TRIAL TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF MN RECOMBINANT SOLUBLE GP120/HIV-1 (RSGP120/HIV-1) (GENENTECH) IN COMBINATION WITH QS21 ADJUVANT AND/OR ALUM IN HEALTHY ADULTS: